Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities
Identifieur interne : 000045 ( Main/Exploration ); précédent : 000044; suivant : 000046Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities
Auteurs : RBID : ISTEX:259_1996_Article_BF01084376.pdfEnglish descriptors
- KwdEn :
Abstract
Radiolabelled somatostatin analogues are of potential value in the imaging of somatostatin receptor-positive tumours. Recently, somatostatin receptors have been demonstrated in the osteoblast precursor cells. In this preliminary study, we evaluated the uptake characteristics of indium-111 octreotide in two benign and two malignant bone tumours. Tracer accumulation was observed in all four cases, and overall lesion to background ratio (mean±SD) was 2.74±0.84 and 2.98±1.49 at 4 h and 24 h, respectively. There was no clear relationship between I111In-octreotide accumulation and the benign or malignant nature of the tumour. In one patient, tracer uptake was inhibited by unlabelled octreotide administration. These results suggest that111In-octreotide can be taken up by benign and malignant bone tumours. The inhibition of tumour uptake by treatment with cold octreotide supports the concept that specific uptake mechanisms are responsible for111In-octreotide deposition by bone tumours.
DOI: 10.1007/BF01084376
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities</title><author><name>Sabahat Inanir</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Gazi University Medical Faculty, Ankara, Turkey</mods:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Nuclear Medicine, Gazi University Medical Faculty, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name>Mustafa Ünlü</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Gazi University Medical Faculty, Ankara, Turkey</mods:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Nuclear Medicine, Gazi University Medical Faculty, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name>Berna Okudan</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Gazi University Medical Faculty, Ankara, Turkey</mods:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Nuclear Medicine, Gazi University Medical Faculty, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name>Erdal Cila</name><affiliation wicri:level="1"><mods:affiliation>Department of Orthopedics, Gazi University Medical Faculty, Ankara, Turkey</mods:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Orthopedics, Gazi University Medical Faculty, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author><name>Sahap Atik</name><affiliation wicri:level="1"><mods:affiliation>Department of Orthopedics, Gazi University Medical Faculty, Ankara, Turkey</mods:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Orthopedics, Gazi University Medical Faculty, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1996_Article_BF01084376.pdf</idno><date when="1996">1996</date><idno type="doi">10.1007/BF01084376</idno><idno type="wicri:Area/Main/Corpus">000580</idno><idno type="wicri:Area/Main/Curation">000580</idno><idno type="wicri:Area/Main/Exploration">000045</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bone tumour</term><term>Octreotide</term><term>Receptor imaging</term><term>Somatostatin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Radiolabelled somatostatin analogues are of potential value in the imaging of somatostatin receptor-positive tumours. Recently, somatostatin receptors have been demonstrated in the osteoblast precursor cells. In this preliminary study, we evaluated the uptake characteristics of indium-111 octreotide in two benign and two malignant bone tumours. Tracer accumulation was observed in all four cases, and overall lesion to background ratio (mean±SD) was 2.74±0.84 and 2.98±1.49 at 4 h and 24 h, respectively. There was no clear relationship between I111In-octreotide accumulation and the benign or malignant nature of the tumour. In one patient, tracer uptake was inhibited by unlabelled octreotide administration. These results suggest that111In-octreotide can be taken up by benign and malignant bone tumours. The inhibition of tumour uptake by treatment with cold octreotide supports the concept that specific uptake mechanisms are responsible for111In-octreotide deposition by bone tumours.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="651cb6eb72264434608fda3b81a4b3b1d9894632"><titleInfo lang="eng"><title>Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities</title></titleInfo><name type="personal"><namePart type="given">Sabahat</namePart><namePart type="family">Inanir</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Gazi University Medical Faculty, Ankara, Turkey</affiliation></name><name type="personal"><namePart type="given">Mustafa</namePart><namePart type="family">Ünlü</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Gazi University Medical Faculty, Ankara, Turkey</affiliation></name><name type="personal"><namePart type="given">Berna</namePart><namePart type="family">Okudan</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Gazi University Medical Faculty, Ankara, Turkey</affiliation></name><name type="personal"><namePart type="given">Erdal</namePart><namePart type="family">Cila</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Orthopedics, Gazi University Medical Faculty, Ankara, Turkey</affiliation></name><name type="personal"><namePart type="given">Sahap</namePart><namePart type="family">Atik</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Orthopedics, Gazi University Medical Faculty, Ankara, Turkey</affiliation></name><typeOfResource>text</typeOfResource><genre>Short Communication</genre><genre>Brief Communication</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1996-02-15</dateCreated><dateValid encoding="w3cdtf">2005-01-03</dateValid><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">Radiolabelled somatostatin analogues are of potential value in the imaging of somatostatin receptor-positive tumours. Recently, somatostatin receptors have been demonstrated in the osteoblast precursor cells. In this preliminary study, we evaluated the uptake characteristics of indium-111 octreotide in two benign and two malignant bone tumours. Tracer accumulation was observed in all four cases, and overall lesion to background ratio (mean±SD) was 2.74±0.84 and 2.98±1.49 at 4 h and 24 h, respectively. There was no clear relationship between I111In-octreotide accumulation and the benign or malignant nature of the tumour. In one patient, tracer uptake was inhibited by unlabelled octreotide administration. These results suggest that111In-octreotide can be taken up by benign and malignant bone tumours. The inhibition of tumour uptake by treatment with cold octreotide supports the concept that specific uptake mechanisms are responsible for111In-octreotide deposition by bone tumours.</abstract><subject lang="eng"><genre>Key words</genre><topic>Somatostatin</topic><topic>Octreotide</topic><topic>Receptor imaging</topic><topic>Bone tumour</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1996</partNumber><partNumber>Volume: 23</partNumber><partNumber>Number: 8</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1996-08-01</dateIssued><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 31</identifier><recordInfo><recordOrigin>Springer-Verlag, 1996</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF01084376</identifier><identifier type="matrixNumber">Art19</identifier><identifier type="local">BF01084376</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>987</start><end>990</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1996</recordOrigin><recordIdentifier>259_1996_Article_BF01084376.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000045 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000045 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1996_Article_BF01084376.pdf
|texte= Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities
}}
| This area was generated with Dilib version V0.5.81. |  |